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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:
To determine the sensitivity, specificity, and positive and negative predictive value of 1) the presence of one or more tuberculosis
symptoms, or symptom combinations; 2) chest radiography; 3) Xpert MTB/RIF; 4) Xpert Ultra; and 5) combinations of the aforementioned
tests as screening tests for detecting active pulmonary tuberculosis in children in the following groups.
• Household contacts of a person with active tuberculosis;
• School contacts of a person with active tuberculosis;
• Other close contacts of a person with active tuberculosis;
• Children living with HIV;
• Children with pneumonia;
• Other risk groups (e.g. children with a history of previous tuberculosis, malnourished children);
• Children in the general population in high burden settings
Secondary objectives
To compare the accuracy of the diJerent index tests, including diJerent applications of tests (e.g. CXR with any abnormality versus, more
specifically, CXR with abnormality suggestive of tuberculosis); we are interested in the accuracy of the index tests in any setting (i.e.
community, outpatient, and inpatient).
To investigate potential sources of heterogeneity in accuracy estimates in relation to age group, HIV status, whether the study was
conducted in a high tuberculosis burden country, and whether the child received a single screening or more than one screening.
Screening tests for active pulmonary tuberculosis in children (Protocol)
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B A C K G R O U N D
Tuberculosis continues to elude traditional control strategies.
According to the WHO Global TB Report 2019, an estimated 10
million people in 2018 fell ill with tuberculosis worldwide. Of these,
over 25% were not diagnosed or reported to the World Health
Organization (WHO). Children less than 15 years old represented
approximately 11% of incident cases but 14% of the estimated
1.3 million deaths from tuberculosis in 2018. This relatively higher
share of mortality in children highlights urgent needs of improved
case detection and subsequent access to treatment in this age
group (WHO Global TB Report 2019).
Case finding is a crucial step in the cascade of care for patients
with tuberculosis; however, for most deaths from tuberculosis
in children, the disease is never diagnosed (Jenkins 2017). In
the "Roadmap towards ending TB in children and adolescents,"
the WHO identifies case finding for child tuberculosis as a key
activity (WHO 2018). Major factors lead to underdiagnosis of
tuberculosis in children including the following: 1) symptoms tend
to be less specific in children and overlap with those of other
common childhood diseases; 2) existing tests for children are
invasive and have suboptimal sensitivity; ideally, tests need to be
inexpensive, accessible, and usable at the point of care, allowing
for actionable information for patient care; and 3) reliance on a
clinical diagnosis of tuberculosis, without microbiological evidence
of disease, requires expertise, which is oNen not available in areas
where the burden of disease is greatest. Given these factors,
national and international guidelines for child health generally lack
systematic screening strategies for tuberculosis (WHO 2018).
For adult populations, systematic screening for tuberculosis in
high-risk groups and vulnerable populations is a more established
strategy to improve case detection in high burden settings.
In 2013, the WHO published “Systematic screening for active
tuberculosis: principles and recommendations.” This document
provided guidance for the development of screening approaches
for adult populations (WHO 2013a). A Cochrane Protocol (van’t
Hoog 2014) and an ensuing non-Cochrane systematic review (van’t
Hoog 2013) contributed to the WHO recommendations (WHO
2013a). Participants included in the systematic review were adults
15 years and older. The review excluded studies of children 0 to
5 years of age or studies of child tuberculosis only. Since 2013,
estimation of the true burden of child tuberculosis has improved
and several promising strategies for case finding are being either
newly implemented or developed (Schumacher 2019; Stop TB
Partnership 2019). With this, there is a new call to push forward
systematic screening for active tuberculosis in children (Reuter
2019; WHO 2018). This review will address tuberculosis screening
strategies in children less than 15 years of age.
Screening
Tuberculosis screening is a term that has been used diJerently
in the literature depending on the context. We have adopted
the definition of tuberculosis screening from the WHO as "the
systematic identification of people with suspected active TB,
in a predetermined target group, using tests, examinations or
other procedures that can be applied rapidly" (WHO 2013a; WHO
2015).” The WHO's more recent End-TB strategy emphasizes early
diagnosis of tuberculosis and systematic screening of contacts
and high-risk groups (WHO 2018), which is in line with the above
definition of tuberculosis screening.
Target condition being diagnosed
Tuberculosis is a communicable disease caused by the bacterium
Mycobacterium tuberculosis (M tuberculosis). A small fraction
of those with tuberculosis infection initially develop active
tuberculosis (tuberculosis disease). More commonly, initial
infection leads to latent tuberculosis infection, which has the
potential to become active tuberculosis throughout an individual’s
lifetime, especially during states of immunosuppression such as
HIV infection and malnutrition. M tuberculosis is transmitted from
person to person through the air and, therefore, most commonly
causes disease in the lungs, referred to as pulmonary tuberculosis.
Tuberculosis can, however, occur in any organ or tissue outside of
the lungs (termed extrapulmonary tuberculosis), with lymph node
tuberculosis as the most common form and tuberculous meningitis
as the most severe form of extrapulmonary disease. As the most
common form of active tuberculosis is lung disease, most screening
studies in adults and children evaluate tests and strategies for
pulmonary tuberculosis and verify tuberculosis using respiratory
specimens. In this review, the target condition will be pulmonary
tuberculosis.
Signs and symptoms of pulmonary tuberculosis include fever,
cough, night sweats, weight loss or poor weight gain, visible neck
mass and lethargy or decreased activity/playfulness. However,
pulmonary tuberculosis symptoms in children, especially those
under five years of age, tend to be less specific because they
oNen overlap with other common paediatric conditions such
as pneumonia, HIV-associated lung disease, and malnutrition
(Jaganath 2012; Oliwa 2015). Compared to adults, children are
much more likely to progress from latent tuberculosis infection
to tuberculosis disease. Further, among those progressing to
disease, younger children are more likely to experience severe
manifestations (Marais 2004; Marais 2014).
Microbiological confirmation of pulmonary tuberculosis in children
is complicated by two main factors. First, younger children are
not able to voluntarily expectorate sputum, which is the standard
specimen used for microbiological detection of pulmonary
tuberculosis in adults. Therefore, specimens from young children
traditionally are collected from more invasive methods such as
gastric aspiration and sputum induction (Graham 2015). Second,
lung cavities with high bacillary load as seen in adult pulmonary
tuberculosis is uncommon in children, especially in young children
(< 10 years of age). The number of bacilli causing disease in children
tends to be low and the 'paucibacillary' nature of their disease
compromises diagnostic yield (Dunn 2016).
Index test(s)
This review includes the following index tests used in screening for
pulmonary tuberculosis in children: tuberculosis symptoms, chest
radiography (CXR), Xpert MTB/RIF and Xpert Ultra, and various
combinations of these tests.
With symptom screening, individuals or their caregivers
are interviewed about symptoms suggestive of pulmonary
tuberculosis such as cough of varying duration, fever of varying
duration, weight loss or poor weight gain, night sweats, visible neck
mass, and decreased activity. Though not a true symptom, contact
with individuals with tuberculosis is another important factor when
interviewing for tuberculosis risk (Graham 2015).
Screening tests for active pulmonary tuberculosis in children (Protocol)
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CXR can involve posterior-anterior, anterior-posterior, and/
or lateral recording. Commonly used types of CXR include
conventional CXR (producing 36 cm x 43 cm film), digital
radiography, and computed radiography. The most common
radiographic finding of pulmonary tuberculosis in children is
hilar lymphadenopathy (Leung 1992), though CXR has limitations
identifying this finding (Swingler 2005). Accurate interpretation of
CXR findings for pulmonary tuberculosis in children is dependent
on the ability of the individual interpreting the CXR, and wide
interobserver variation has been reported (Du 2002; Kaguthi 2014).
Computer-aided interpretation of CXR for pulmonary tuberculosis
is a promising new technology, especially for resource-limited
settings where expertise in CXR interpretation is limited (Qin 2019;
Sodhi 2017), but this technology has currently not been assessed in
children (Reuter 2019).
Xpert MTB/RIF and Xpert Ultra, the newest version, (Cepheid Inc,
CA, USA) are nucleic acid amplification tests (NAAT) that can
detect both M tuberculosis DNA and rifampicin resistance. We will
not assess rifampicin resistance in this review. These two assays
are completely automated and self-contained once the sample is
loaded into the cartridge. Specimen processing is similar for both
Xpert MTB/RIF and Xpert Ultra using Xpert Sample Reagent and
requires 15 minutes of incubation. Within two hours, results are
available. Consistent supply of electricity, temperature control, and
annual calibration of the cartridge modules are needed for Xpert
MTB/RIF and Xpert Ultra (Global Laboratory Initiative 2019). Xpert
Ultra has approximately 1-log improvement in the lower limit of
detection of bacterial load compared to previous generations of the
test (Chakravorty 2017). Xpert Ultra also has a new result category,
'trace call,' that represents minimally detectable bacillary burden.
According to the WHO, a 'trace call' result is adequate to prompt
initiation of anti-tuberculosis therapy in children or people living
with HIV (WHO 2017b). The WHO recommends the use of Xpert
MTB/RIF and Xpert Ultra as initial diagnostic tests for pulmonary
tuberculosis in adults and children. Specifically in children, the
guidelines recommend use of a variety of specimen types for
diagnosis including gastric specimens, nasopharyngeal specimens,
and stool specimens, in addition to sputum (WHO 2020). We will
include Xpert MTB/RIF (all versions) and Xpert Ultra in this review.
Another WHO-recommended NAAT for detection of tuberculosis
is the TrueNat assay (Molbio Diagnostics/Bigtec Labs, Goa/
Bengaluru, India) (WHO 2020). However, to our knowledge, there
are currently no published studies assessing this test in children.
We plan to include TrueNat in this review if data become available
while we perform the review.
Clinical pathway
As shown in Figure 1, there are two complementary approaches to
detection of tuberculosis disease. The first is the patient-initiated
pathway, also known as passive case finding. The second is the
provider-initiated screening or active case finding pathway (WHO
2015), which is the analytic framework for this review. One major
challenge with either pathway is that 'high quality diagnosis'
is elusive for child tuberculosis, especially for younger children
and children in resource-limited settings. This diagram also
demonstrates the wide range of potential target populations for
tuberculosis screening in children, ranging from contacts of those
with tuberculosis ('exposed') to symptomatic patients accessing
healthcare (e.g. children living with HIV, as described above). This
review will include evidence from all of these systematic screening
strategies.
 
Figure 1.   There are two complementary approaches to detection of tuberculosis disease. The first is the patient-
initiated pathway, also known as passive case finding. The second is the provider-initiated screening pathway (WHO
2015), which is the analytic framework for this review. One major challenge with either pathway is that 'high quality
diagnosis' is elusive for child tuberculosis, especially for younger children and in resource-limited settings. This
diagram also demonstrates the wide range of potential target populations for tuberculosis screening, ranging from
contacts of those with tuberculosis ('exposed') to symptomatic patients accessing healthcare, such as children
living with HIV. Copyright © [2015] [World Health Organization]: reproduced with permission.
 
There is no standard screening approach for children less than
15 years old. For the subgroup of children living with HIV, since
2011 the WHO has recommended symptom screening for all
children living with HIV presenting to healthcare facilities. Under
Screening tests for active pulmonary tuberculosis in children (Protocol)
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this guideline, children living with HIV older than 12 months
of age presenting with any cough, fever, weight loss or poor
weight gain, or history of contact with someone with tuberculosis
should be further investigated for tuberculosis. In the absence
of any of these four symptoms, they "are unlikely to have active
TB." Although this 'strong recommendation' was based upon
'low quality evidence' (WHO 2011), it exemplifies a standardized
screening approach for tuberculosis that is otherwise lacking for
the paediatric population.
Screening may use sequential or parallel strategies (Figure 2).
With sequential strategies, only those with a positive result in the
first step are screened in the second step. With parallel screening
strategies, multiple diJerent screens are done initially, and any
positive screen or combinations of positive screens prompts
further investigation (i.e. confirmatory test) for the target condition.
Results from various screening strategies will be included in this
review. We will consider individuals’ results to be ‘true screen
positives’ if they were rightfully referred for confirmatory testing;
in contrast, we will consider individuals’ results to be ‘false screen
positives’ if the individuals were referred for confirmatory testing
but not diagnosed with tuberculosis. Although individuals with
negative screens should not undergo confirmatory testing during
routine clinical practice, individuals with negative screens may
complete confirmatory testing in a research context to establish
true screen negatives and false screen negatives. As described in
Types of studies, studies that only conduct confirmatory testing on
those with positive screens will be analysed in this review. In the
context of this review, the purpose of the index tests is considered
to be 'screening', and their role is considered to be triage tests. With
triage tests, the index test is used prior to an existing test or strategy,
and only those with a specific result on the triage test continue
along the clinical pathway (Bossuyt 2006).
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Figure 2.   Di@erent screening and diagnostic algorithms
 
Alternative test(s)
Two types of immunologic tests not included in this review are
the tuberculin skin test (TST) and the interferon gamma release
assay (IGRA). Both of these methods are dependent on the
cellular immune response to M tuberculosis antigens in individuals
previously exposed to the organism, and neither can distinguish
between latent tuberculosis infection and active tuberculosis
disease (Pai 2014). Further, neither method is sensitive enough to
serve as a rule out test for tuberculosis disease in children but rather
may be used to support tuberculosis diagnosis. The TST has been
in clinical use for over a century and involves intradermal injection
of M tuberculosis purified protein derivative. Drawbacks to the TST
include the need for a second clinical encounter 48 to 72 hours
aNer placement for result interpretation, inter-reader variability,
a tendency for previous bacillus Calmette-Guerin vaccination to
result in false-positive results, and a tendency for false-negative
results in immunosuppressed individuals or due to anergy in
individuals with active disease (Pai 2014).
Commercially available IGRAs include QuantiFERON-TB Gold In-
tube (QFT-GIT; Qiagen, Germantown, MD), QuantiFERON-TB Gold
Plus (QFT-Plus; Qiagen) and T-SPOT.TB (Oxford Immunotec Ltd,
Oxford, United Kingdom). To improve upon the TST, IGRAs were
developed to measure release of interferon gamma from T cells
stimulated by antigens specific to M tuberculosis. The QFT-GIT
assay stimulates interferon gamma release from CD4+ T cells,
while the QFT-Plus assay can stimulate both CD4+ and CD8+ T
cell responses. CD8+ cytotoxic T cells have been shown to have
higher responses in subjects with active pulmonary tuberculosis
compared to latent tuberculosis infection (Day 2011; Rozot 2013).
Screening tests for active pulmonary tuberculosis in children (Protocol)
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Individuals with low CD4+ T cell counts (e.g. those with advanced
HIV) have been shown to maintain CD8+ T cell antigen responses to
M tuberculosis (Sutherland 2010). For these reasons, it is theorized
that the QFT-Plus assay may be more sensitive for those with active
tuberculosis and people living with HIV (Theel 2018). The T-SPOT.TB
is an enzyme-linked immunoassay that involves incubation of
separated and counted peripheral blood mononuclear cells with
antigens specific to M tuberculosis. If the number of interferon
gamma-producing T cells (spot-forming cells) exceeds a specific
threshold relative to negative control wells, the result is positive.
All IGRAs utilize positive and negative controls, and they can have
indeterminate results if there is a low interferon gamma response
in the positive control or if there is a high response in the negative
control (Pai 2014).
Beyond the index tests described above, there are a number of
alternative approaches and tests for screening (or diagnosis) of
tuberculosis in children. Prior to the widespread roll out of Xpert
MTB/RIF worldwide over the past decade, testing for tuberculosis
mostly relied upon examination of sputum smears for acid-fast
bacilli under a light microscope using the classical Ziehl-Neelsen
staining technique, fluorescence microscopy, or light-emitting
diode (LED)-based fluorescence microscopy. A recent review found
that in children, the sensitivity of smear microscopy was about 22%
in gastric specimens and about 29% in expectorated and induced
sputum specimens (WHO 2013b).
A variety of newer assays detect lipoarabinomannan (LAM)
antigen in urine of people with tuberculosis disease. LAM is a
lipopolysaccharide present in the mycobacterial cell wall. Urine
LAM assays have the advantages of being non-invasive and rapid.
Currently, the only rapid commercially available LAM assay is the
Determine TB-LAM (Alere, Waltham, MA, USA). Based on evidence
from randomized trials and a Cochrane Review (Bjerrum 2019), the
WHO recommends that AlereLAM should be used to assist in the
diagnosis of active tuberculosis in HIV-positive adults, adolescents,
and children. The full recommendations, which diJer for inpatients
and outpatients, are described here: WHO Lateral flow LAM 2019.
Another LAM assay expected to become commercially available in
2020 is the Fujifilm SILVAMP TB-LAM (Fujifilm, Tokyo, Japan). Early
evidence for this assay demonstrates superior sensitivity compared
to AlereLAM for adults living with HIV (Bjerrum 2020, Broger 2019).
It is noteworthy that development of novel tools for detection
of tuberculosis disease is a very active field. Noteworthy tests
with emerging evidence include C-reactive protein (Albuquerque
2019), IP-10 (Alsleben 2011; Holm 2014; Jenum 2016; Sudbury 2019;
Tebruegge 2015), and C-Tb (Statens Serum Institut, Copenhagen
(Aggerbeck 2019; Ruhwald 2017). Over the next decade, more
eJicient technologies are anticipated with the hope that these
will advance screening strategies and reduce the burden of child
tuberculosis worldwide (Schumacher 2019; Stop TB Partnership
2019; WHO 2017a).
Rationale
EJective screening for active tuberculosis in children supports
timely and reliable diagnosis, which is essential for reducing
tuberculosis-attributable morbidity and mortality. EJective
screening also supports disease rule out, thereby guiding
treatment for latent tuberculosis infection and preventive
treatment for exposed or other high-risk groups such as
people living with HIV. Historically, screening children for active
tuberculosis has been limited by the lack of accurate screening and
diagnostic tools. Therefore, systematic screening in children has
only been performed within specific populations with increased
risk of disease to limit the risk of false-positive test errors
and consequent over-treatment of tuberculosis. Guidance from
the WHO states that "only children who are close contacts of
someone with tuberculosis and HIV-positive children should be
systematically screened for TB" (WHO 2015). Optimal screening
strategies for these two high-risk groups are lacking, particularly
in resource-limited settings (Szkwarko 2017, WHO 2011). Further,
limiting systematic screening to child contacts and HIV-positive
children propagates missed opportunities as evidence has
identified other high-risk groups of children in certain settings and
with health conditions, such as malnutrition or pneumonia, who
are also at risk of tuberculosis (Arscott-Mills 2014, Chisti 2014;
LaCourse 2014; Munthali 2017; Oliwa 2015). Finally, increasing
evidence demonstrates that children have considerable risk of
tuberculosis exposure outside of their homes with up to 70% to 90%
of children with tuberculosis having no known exposure (Martinez
2019).
This Cochrane Review will inform an upcoming WHO meeting to
update guidelines for systematic screening for active tuberculosis.
To our knowledge, this is the first systemic review on this topic in
children. There have been several systematic reviews evaluating
the diagnostic accuracy of the index tests described above for active
tuberculosis, including an ongoing Cochrane Review evaluating
Xpert MTB/RIF and Xpert Ultra in children (Kay 2019). The lack of
knowledge regarding the performance of screening tests in children
likely reflects the predominance of paediatric research which has
assessed the performance of tuberculosis tests for diagnosis rather
than screening. The current review will shed light on the potential
of these tools for systematic screening for active pulmonary
tuberculosis in children in specific high-risk populations.
O B J E C T I V E S
To determine the sensitivity, specificity, and positive and negative
predictive value of 1) the presence of one or more tuberculosis
symptoms, or symptom combinations; 2) chest radiography;
3) Xpert MTB/RIF; 4) Xpert Ultra; and 5) combinations of the
aforementioned tests as screening tests for detecting active
pulmonary tuberculosis in children in the following groups.
• Household contacts of a person with active tuberculosis;
• School contacts of a person with active tuberculosis;
• Other close contacts of a person with active tuberculosis;
• Children living with HIV;
• Children with pneumonia;
• Other risk groups (e.g. children with a history of previous
tuberculosis, malnourished children);
• Children in the general population in high burden settings
Secondary objectives
To compare the accuracy of the diJerent index tests, including
diJerent applications of tests (e.g. CXR with any abnormality
versus, more specifically, CXR with abnormality suggestive of
tuberculosis); we are interested in the accuracy of the index tests in
any setting (i.e. community, outpatient, and inpatient).
Screening tests for active pulmonary tuberculosis in children (Protocol)
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To investigate potential sources of heterogeneity in accuracy
estimates in relation to age group, HIV status, whether the study
was conducted in a high tuberculosis burden country, and whether
the child received a single screening or more than one screening.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include cross-sectional studies, cohort studies, and
randomised controlled trials that assessed the accuracy of at least
one of the defined index tests for pulmonary tuberculosis. We will
only include studies that used a microbiologic reference standard
(defined below). We will include studies from all settings and time
periods. Randomized controlled trials will be included because
these studies may report sensitivity and specificity in addition to
patient health outcomes. For randomised studies that compare
diJerent screening strategies, we will evaluate each arm as a
separate cohort. Data on the index test(s) must be available to be
extracted as true positive, false positive, true negative, and false
negative against the reference standard(s) so that we can construct
two-by-two contingency tables.
Studies applying index tests multiple times to an individual within
a short timeframe (e.g. within a single hospital admission), will
be considered diagnostic rather than using a screening approach,
and these studies will be excluded. Studies in which children with
negative screening test results were not subjected to the reference
standard will be included. As shown in Figure 2, this oNen occurs
in tuberculosis prevalence studies when it is assumed that those
with a negative screen (e.g. no CXR abnormalities) do not have
active tuberculosis. However, this leads to poor enumeration of
true negative and false negative test results. Therefore, we will only
include such studies that partially verified tuberculosis status if
they were conducted prospectively and enrolled a consecutive or
random sample of eligible children. Our rationale for specifying
these strict design criteria is to enable us to calculate positive
predictive values from such studies and include them in a separate
set of analyses. Due to the direct relationship between prevalence
and predictive values, to reduce potential variation in prevalence
between studies, we will only include studies in the analyses
of positive predictive value if the studies were done in the
same setting (e.g. community or accessing healthcare), target
population, and for the same purpose (e.g. contact tracing).
We will include cohort studies with children with active
tuberculosis identified aNer the time point that the screening
test was applied. Especially with studies performed in settings
of intended use, the collection of specimens and conduct of the
reference standard may occur some time aNer the screening test
was done. In low resource-settings, this process may take weeks.
However, a longer time between the index test and the reference
standard would make us less sure that the target condition did not
change between the two tests. We will address this issue in the
QUADAS-2 domain 4: Flow and timing and with a sensitivity analysis
(see Sensitivity analyses).
We will exclude case reports and case-control studies, the latter
because of the high risk of bias in diagnostic accuracy studies
(Rutjes 2006).
Participants
We will include studies enrolling HIV-positive and HIV-negative
children younger than 15 years old not known to have active
tuberculosis prior to screening. We will exclude studies if they
include older children and we are unable to extract data for
children younger than 15 years old from the publication. We
will include children in the general population in high burden
settings, children living in areas of high tuberculosis burden,
and high-risk groups, including children younger than five years
old; children living with HIV; children with recent exposure to a
person with active tuberculosis; and household, school, or other
contacts of a person with active tuberculosis. We will include
studies in which children are screened only once and studies
that report longitudinal screening with repeated screening tests at
predetermined intervals.
Index tests
For symptom screening, we will include studies that assess
symptoms of tuberculosis or combinations of symptoms as
described by the primary study authors. Symptoms of active
tuberculosis in children may include cough, fever, decreased
appetite, weight loss or failure to thrive, and fatigue or reduced
playfulness. Older children may experience symptoms similar to
those in adults and include persistent cough, haemoptysis, and
weight loss, fever, night sweats and fatigue. The threshold was
presence or absence of symptoms.
For CXR screening, we will include studies that utilize conventional
radiography, digital radiography, and computed radiography. We
will include all classification systems for identification of CXR
abnormalities, including automated interpretation of radiography
using deep learning or artificial intelligence technology. We will
categorize all CXR screening results as follows. We will use an author
defined threshold for CXR results. Essentially this is an implicit
threshold utilized by the CXR reader.
• Normal.
• Any CXR abnormality, i.e. abnormalities suggestive of
tuberculosis and other abnormalities.
• Abnormalities suggestive of tuberculosis.
For Xpert MTB/RIF and Xpert Ultra, we will include studies in which
the index tests are evaluated in expectorated or induced sputum,
gastric aspirate specimens, nasopharyngeal aspirate specimens,
and bronchoalveolar lavage specimens. Tuberculosis bacilli in
sputum can be swallowed and detected in stool so we will also
include studies assessing stool specimens. We will include studies
assessing more than one type of respiratory specimen collected at
the same time and extract 2 x 2 data separately for each specimen
type.
Xpert MTB/RIF provides the following printed test results:
• MTB (M tuberculosis) DETECTED; Rif (rifampicin)resistance
DETECTED;
• MTB DETECTED; Rif resistance NOT DETECTED;
• MTB DETECTED; Rif resistance INDETERMINATE;
• MTB NOT DETECTED;
• INVALID (the presence or absence of MTB cannot be
determined);
• ERROR (the presence or absence of MTB cannot be determined);
Screening tests for active pulmonary tuberculosis in children (Protocol)
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• NO RESULT (the presence or absence of MTB cannot be
determined).
Xpert Ultra also gives the following semi-quantitative
classifications of M tuberculosis bacterial burden from the sample:
trace, very low, low, moderate, and high. For this review, Xpert MTB/
RIF and Xpert Ultra results will be categorized as:
• Positive: 'MTB DETECTED,' including 'trace' results from Xpert
Ultra
• Negative: 'MTB NOT DETECTED'
• Inconclusive: 'INVALID,' 'ERROR,' or 'NO RESULT'
We will not evaluate rifampicin resistance in this review.
As shown in Figure 2, with two parallel screening tests, the parallel
strategy will entail any of the individual components of the strategy
being positive resulting in a positive parallel strategy screen and
all individual components being negative resulting in a negative
parallel strategy screen. For studies assessing parallel screening
tests, if data for the individual components of the parallel strategy
against the reference standard is also available, these data will also
be extracted for analysis.
Target conditions
The target condition is active pulmonary tuberculosis.
We anticipate that some studies may evaluate the index tests
for active tuberculosis and not explicitly state 'pulmonary
tuberculosis', the target condition in this review. We will include
these studies because the most common type of active tuberculosis
in children is lung disease; hence, most screening studies in
children evaluate tests for pulmonary tuberculosis and diagnose
tuberculosis using respiratory specimens. If data are suJicient, we
will perform a sensitivity analysis limiting inclusion to those studies
that explicitly evaluated the index tests for pulmonary tuberculosis.
Reference standards
We will utilize two reference standards, a microbiological and a
composite reference standard.
Microbiological reference standard
Confirmed pulmonary tuberculosis will be defined as a positive
culture (on solid or liquid medium) or a positive Xpert MTB/RIF or
Xpert Ultra test from a respiratory specimen. When either the Xpert
MTB/RIF or Xpert Ultra test is the index test, we will not include the
test as a reference standard to avoid incorporation bias. We will not
include studies where sputum smear microscopy is the reference
standard.
Collection of multiple respiratory specimens may improve the
diagnostic yield of testing for tuberculosis in children (Cruz 2012;
Zar 2012). With respect to the microbiological reference standard,
we will include studies that involve multiple specimens collected
over time. In these studies, we will utilize the classification of
the reference standard as defined by the primary study authors
(most commonly at least one positive result representing a positive
reference test).
Composite reference standard
We will define the composite reference standard as microbiological
confirmation (as above) or author-defined clinical pulmonary
tuberculosis. Clinical pulmonary tuberculosis must include a
component of follow-up to verify the diagnosis of active
tuberculosis. The consensus research definition of clinical
tuberculosis in children (Graham 2015) is likely too restrictive for
the purpose of this review. Two of our index tests, symptoms and
CXR, are typically components of case definitions used to support
the clinical diagnosis of tuberculosis (i.e. not microbiologically
confirmed). This raises the potential for incorporation bias with the
composite reference standard, i.e. where the result of the index
test is used to help determine the reference standard diagnosis.
Therefore, we will assess the composite reference standard for
incorporation bias using QUADAS-2, which will be enhanced with
the following additional signalling question: "Was incorporation
bias avoided (inclusion of index test as part of the reference
standard)?" In addition, we will discuss incorporation bias as a
limitation of the review.
We will define 'not tuberculosis' as negative microbiological
test results and establishment of alternative diagnosis during
the evaluation for tuberculosis, resolution of symptoms without
tuberculosis treatment, or no progression of symptoms for at least
one month without tuberculosis treatment.
Search methods for identification of studies
We will attempt to identify all relevant published studies regardless
of language. We will describe unpublished studies in the Ongoing
studies section of the review. Although they will not be assessed
as index tests in this review, we will include immunologic tests in
the search strategy. This will allow for archiving of relevant studies
for a future systematic review assessing immunologic tests as index
tests.
Electronic searches
We will search the following databases without language
restriction, using the search terms and strategy described in
Appendix 1.
• MEDLINE and MEDLINE in Process (OVID), from 1946.
• Embase (OVID), from 1947.
• Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library.
• Scopus (Elsevier, from 1970).
We will also search ClinicalTrials.gov, the WHO International
Clinical Trials Registry Platform (ICTRP; www.who.int/trialsearch),
and the International Standard Randomized Controlled Trials
Number (ISRCTN) registry (www.isrctn.com/) for trials in progress.
Searching other resources
To identify any relevant published data not identified with our
electronic search, we will contact experts in the field, and check
the references of relevant reviews from the past ten years. With the
studies selected for inclusion in this review, we will perform forward
and backward reference checking to identify any additional eligible
studies.
Screening tests for active pulmonary tuberculosis in children (Protocol)









Cochrane Database of Systematic Reviews
Data collection and analysis
Selection of studies
We will use Covidence to manage the selection of studies
(Covidence 2017). Two review authors (BV and TN) will
independently screen all titles and abstracts from the electronic
searches to identify potentially eligible studies. We will obtain full-
text articles of potentially eligible studies, and the two review
authors (BV and TN) will independently assess the full-text articles
for study eligibility using the predefined inclusion and exclusion
criteria. We will resolve any disagreements by discussion or with
a third review author (AMM). As needed, we will contact study
authors to clarify the study methods and other information.
Studies excluded during the full-text review will be listed in the
'Characteristics of excluded studies' table with a summary of
reasons for exclusion. We will illustrate the study selection process
in a PRISMA flow diagram (Moher 2009).
Data extraction and management
We will design a data extraction form and pilot it on at least
two included studies. ANer reviewing the piloted forms with the
other review authors, we will finalize the form. Two review authors
will use the data extraction form to independently extract data
from the included studies. We will discuss any inconsistencies with
a third review author. We will enter the extracted data into an
Excel database (Excel 2013) on password-protected computers and
secured in the cloud storage Dropbox for future review updates.
We will extract the following information for each included study.
Study details
• First author, title, year of publication, journal, language.
• Study design, sampling method, prospective/retrospective, and
inclusion criteria for presumptive tuberculosis (if any).
• Number of participants aNer screening for exclusion and
inclusion criteria.
• Number of children included in the systematic review analysis.
• Single or initial screening versus more than one screening in the
population.
• Any sequential or parallel screening strategies.
Patient characteristics and setting
• Description of study population.
• Age: median, mean, range, and disaggregation into categories (0
to 4, 5 to 14)
• Gender.
• HIV status.
• Proportion with severe wasting or severe acute malnutrition.
• Screening location: community, outpatient facility, or inpatient
facility.
• Children with prior tuberculosis included, yes/no? If yes, what
proportion?
• Country/countries where study was conducted
• Country WHO classification for high tuberculosis burden
country (WHO Global TB Report 2019).
• Years of data collection.
Index test
• Definition of positive symptom screen.
• List symptoms assessed.
• Details of timing of contact history (i.e. current, within past year,
beyond one year).
• Types of CXR used.
• Description of radiographic findings classification.
• Type of CXR reader: radiologist, pulmonologist, general medical
oJicer, clinical oJicer, nurse, other.
• Types of respiratory specimens used.
• Types of NAATs used.
• For each index test, number of results that are true positive,
false positive, true negative, false negative, inconclusive, and
missing.
Reference standard
• Microbiological reference standard used: solid culture, liquid
culture, Xpert MTB/RIF, or Xpert Ultra.
• Criteria used for composite reference standard.
• Reference standard applied to all children or only those with a
positive screening test result?
• Number of microbiological tests used to exclude tuberculosis.
• Number of contaminated cultures and total number of cultures
performed.
• Time between the index test and the reference standard.
Assessment of methodological quality
Two review authors will independently assess the methodological
quality of the included studies using the Quality Assessment of
Diagnostic Accuracy Studies (QUADAS-2) instrument, which we will
adapt for this review (Whiting 2011). The preliminary tool with
signalling questions tailored to this review is in Appendix 2. As
recommended, we will assess each of the four domains (patient
selection, index tests, reference standards, and flow and timing)
for risk of bias and the first three domains for concerns regarding
applicability.
We will judge each item as 'yes' (adequately addressed),
'no' (inadequately addressed), or 'unclear' when there is
insuJicient information reported to make an assessment. One
review author will pilot the tool on two included studies. We
will then make any necessary revisions to finalize the tool. We
will resolve disagreements between the two review authors'
independent assessments through discussion or additional input
from a third review author. We will present results of the quality
assessment in text, tables, and graphs.
Statistical analysis and data synthesis
We will perform descriptive analyses of the included studies and
present their key characteristics in the 'Characteristics of included
studies' table and a summary table. We will present individual
study estimates of sensitivity and specificity graphically on forest
plots and in receiver operating characteristics (ROC) space using
Review Manager 5 (RevMan 2020).
We will consider one index test result per child per time point.
However, for studies assessing serial screening over time for
individuals, separate screens may be assessed if they are also
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compared against serial confirmatory tests over time (i.e. multiple
screens for one individual). Within each group listed in Objectives,
we will perform analyses by index tests and reference standards.
For symptom screening as the index test, we plan to perform
analyses by single symptoms and multiple symptoms (such as the
WHO four-symptom screen), where data are available.
We will consider combining categories depending on the number
of studies and screening definitions found in each category. We will
also stratify the analyses by the type of reference standard used,
microbiological or composite. Separate analyses will be performed
for studies that verify participants regardless of their index test
results (i.e. complete verification) and those that only verify test
positives (i.e. partial verification).
When there are suJicient data, we will perform meta-analyses
to estimate summary values of sensitivity and specificity using a
bivariate model (Chu 2006; Reitsma 2005). We chose the bivariate
model because we anticipate dealing with binary test results or
studies that used the same threshold because they applied the
threshold recommended by the test manufacturer. Also, we note
that the bivariate model is appropriate to use for index tests such
as Xpert MTB/RIF and Xpert Ultra, which apply a common positivity
criterion (Macaskill 2010). When we are unable to fit the models
due to sparse data or few studies, we will simplify the models
to univariate random-eJects logistic regression models to pool
sensitivity and specificity separately (Takwoingi 2015). For studies
that verify only test positives, we will pool positive predictive values
using a univariate random-eJects logistic regression model. We
will perform meta-analyses using the meqrlogit command in Stata
version 16 (Stata 16).
For test comparisons, we will exclude studies where one index
test was used as the reference standard for another index test in
the comparison e.g. if Xpert MTB/RIF was used as the reference
standard for CXR. We will perform comparative meta-analyses by
first including all studies with relevant data in indirect comparisons
to make use of all available data. We will then perform additional
analyses by restricting the analyses to only comparative studies
that made direct comparisons between the index tests within
the same study population. Comparative meta-analyses will be
performed using bivariate meta-regression by adding test-type as
a covariate to bivariate models. We will assess model fit using
likelihood ratio tests to compare models with and without the
covariate terms. We will calculate absolute diJerences in sensitivity
and specificity using the model parameters. We will obtain 95%
confidence intervals and P values for the absolute diJerences using
the delta method and Wald tests, respectively.
For subgroups or screening definitions that do not have suJicient
data for a meta-analysis, we will summarize findings using
descriptive methods.
Approach to inconclusive index test results
As described above, the NAAT assays assessed in this review
as index tests may have inconclusive results. We will report the
proportion of inconclusive index test results. Depending on the
available data, we will reclassify these results as positive or
negative and perform additional analyses to determine the impact
of including these test results on test accuracy.
Investigations of heterogeneity
We will visually inspect forest plots and summary ROC (SROC)
plots for heterogeneity. When data allow, we will evaluate potential
sources of heterogeneity using subgroup analyses and bivariate
meta-regression.
For subgroup analyses, we will assess the following subgroups:
children aged 0 to 4 years, children aged 5 to 14 years, HIV positive
children, and HIV negative children.
For meta-regression analyses, we will include high tuberculosis
burden country (yes or no) and single or initial screening
versus more than one screening and consider each source of
heterogeneity as a single covariate in a bivariate model.
Sensitivity analyses
When data allow, we will perform sensitivity analyses and explore
the eJect of risk of bias and study characteristics on the accuracy of
index test results by limiting inclusion in the meta-analyses to the
following.
• Studies that only used consecutive or random selection of
participants.
• Studies with an appropriate interval between the index test and
the reference standard.
• Studies that avoid incorporation bias (inclusion of index test as
part of the reference standard).
• Studies that explicitly evaluated the index tests for pulmonary
tuberculosis.
Assessment of reporting bias
We will not formally assess reporting bias using funnel plots or
regression tests as these have not been reported as helpful for
diagnostic test accuracy studies (Macaskill 2010).
Assessment of certainty of the evidence
We will assess the certainty of evidence using the GRADE approach
for diagnostic studies (Balshem 2011; Schünemann 2008). As
recommended, we will rate the certainty of evidence as either
high (not downgraded), moderate (downgraded by one level),
low (downgraded by two levels), or very low (downgraded by
more than two levels) based on five domains: risk of bias,
indirectness, inconsistency, imprecision, and publication bias. For
each outcome, the certainty of evidence starts as high when there
are high-quality observational studies (cross-sectional or cohort
studies) that enrolled participants with diagnostic uncertainty. If
we find a reason for downgrading, we will use our judgement to
classify the reason as either serious (downgraded by one level) or
very serious (downgraded by two levels).
Three review authors will discuss judgements and apply GRADE in
the following way (Schünemann 2020a; Schünemann 2020b).
Assessment of risk of bias
We will use QUADAS-2 to assess risk of bias.
Indirectness
We will assess indirectness in relation to the population (including
disease spectrum), setting, interventions, and outcomes (accuracy
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measures). We will also use prevalence as a guide to whether there
was indirectness in the population.
Inconsistency
GRADE recommends downgrading for unexplained inconsistency in
sensitivity and specificity estimates. We will carry out prespecified
analyses to investigate potential sources of heterogeneity and
downgrade when we cannot explain inconsistency in the accuracy
estimates.
Imprecision
We will consider a precise estimate to be one that would allow a
clinically meaningful decision. We will consider the width of the CI,
and ask, “Would we make a diJerent decision if the lower or upper
boundary of the CI represented the truth?” In addition, we will work
out projected ranges for TP, FN, TN, and FP for a given prevalence
of tuberculosis and make judgements on imprecision from these
calculations.
Publication bias
We will rate publication bias as undetected (not serious) for several
reasons, including the comprehensiveness of the literature search
and extensive outreach to tuberculosis researchers to identify
studies.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
TB Original Search Strategy Designed for MEDLINE OVID
1.exp child/ or exp infant/
2.exp pediatrics/
3.(newborn* or new-born* or neonat* or neo-nat* or infancy* or infant* or baby* or babies* or toddler*).ti,ab,kw.
4.(child* or boy or boys or girl* or youth* or pediatric* or paediatric* or kid or kids or "school-age*" or juvenile* or preteen* or
tween*).ti,ab,kw.
5.(preteen* or pre-teen* or fiNeen* or fourteen* or thirteen* or teen* or adolescen* or preadolescen* or "pre-adolescen*" or pubescen* or
prepubescen* or "pre-pubescen*").ti,ab,kw.
6.1 or 2 or 3 or 4 or 5
7.exp Mycobacterium tuberculosis/
8.exp Tuberculosis/
9.(tuberculos* or tb* or ptb).ti,ab,kw.
10.7 or 8 or 9
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11.((active* or symptomatic*) adj3 (tuberculosis* or tb*)).ti,ab,kw.
12.("active tuberculos*" or "active tb*").kw.
13.("symptomatic* tuberculos*" or "symptomatic* tb*").kw.
14.11 or 12 or 13
15.10 and 14








24.(fever* or "high* temp*").ti,ab,kw.
25.Weight Loss/
26.("weight loss*" or weightloss*).ti,ab,kw.
27.19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
28.18 and 27
29.exp Radiography, Thoracic/
30.((chest* or lung* or thoracic*) adj3 ("x-ray*" or xray* or radiogra* or imag*)).ti,ab,kw.
31.("chest x-ray*" or "chest xray*" or "chest radiogra*" or "chest imag*").kw.
32.("lung x-ray*" or "lung xray*" or "lung radiogra*" or "lung imag*").kw.
33.("thoracic x-ray*" or "thoracic xray*" or "thoracic radiogra*" or "thoracic imag*").kw.
34.exp tuberculin test/
35.("tubercul* skin test*" or tst or "tb skin test*").ti,ab,kw.
36.exp Interferon-gamma Release Tests/
37.(("interferon-gamma releas*" or "IFN-gamma releas*") adj3 (test* or assay*)).ti,ab,kw.
38.("interferon-gamma releas* test*" or "interferon-gamma releas* assay*").kw.
39.("IFN-gamma releas* test*" or "IFN-gamma releas* assay*").kw.
40.igra.ti,ab,kw.
41.("QuantiFERON-TB*" or QuantiFeronTB* or QFT* or "T-Spot*" or TSpot*).ti,ab,kw.
42.("immunologic* test*" or "immuno-logic test*").ti,ab,kw.
43.("microbiologic* confirm*" or "micro-biologic* confirm*").ti,ab,kw.
44.(("Mycobacter* tubercul*" or MTB) adj3 (culture* or test* or assay*)).ti,ab,kw.
45.("Mycobacter* tubercul* culture*" or "Mycobacter* tubercul* test*" or "Mycobacter* tubercul* assay*").kw.
46.("MTB culture*" or "MTB test*" or "MTB culture*").kw.
47.((tubercul* or TB) adj3 (test* or assay*)).ti,ab,kw.
48.("tubercul* test*" or "tubercul* assay*" or "TB test*" or "TB assay*").kw.
49.((Xpert* or GeneXpert*) adj3 (MTB or RIF or rifampicin* or Ultra)).ti,ab,kw.
50.("Xpert MTB*" or "Xpert RIF*" or "Xpert rifampicin*" or "Xpert Ultra*").kw.
51.("GeneXpert MTB*" or "GeneXpert RIF*" or "GeneXpert rifampicin*" or "GeneXpert Ultra*").kw.
52.(GeneXpert* or Xpert*).ti,ab,kw.
53.(TrueNat or "True-Nat" or TruNat or "Tru-Nat").ti,ab,kw.
54.("nucleic acid amplification test*" or NAAT).ti,ab,kw.
55.18 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51
or 52 or 53 or 54
56. 6 and 15 and 55
We will use this search strategy for Medline OVID and adapt it for the other electronic databases listed.
Appendix 2. QUADAS-2 review-specific guidance
Domain 1: Patient selection
Risk of bias: Could the selection of patients have introduced bias?
Signalling question 1: Was a consecutive or random sample of patients enrolled?
• Yes: if the study enrolled a consecutive or random sample of eligible patients.
• No: if the study selected patients by convenience.
• Unclear: if the study did not report the manner of patient selection or we cannot tell.
Screening tests for active pulmonary tuberculosis in children (Protocol)









Cochrane Database of Systematic Reviews
Signalling question 2: Did the study avoid inappropriate exclusions? Examples of inappropriate exclusions may include children with distant
history of tuberculosis, children experiencing severe signs and symptoms of tuberculosis, or children with negative screening test.
Yes: if no study participants were excluded aNer inclusion.
No: if study participants were excluded.
Unclear: if we cannot tell.
Applicability: Are there concerns that the included patients and setting do not match the review question?
High concern: if the study population does not resemble a population that would be considered for screening for tuberculosis in a
community setting, such as household or schools.
Low concern: if the study population resembles a population that would be considered for screening for tuberculosis in a community
setting; screening program in practice.
Unclear concern: if we cannot tell.
Domain 2: Index test
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Symptom screen, CXR, and Xpert MTB/RIF and Xpert Ultra
Signalling question 1: Were the index test results interpreted without knowledge of the results of the reference standard?
• Yes: if the screening test was performed without knowing whether the person had active tuberculosis. Also, with respect to Xpert MTB/
RIF and Xpert Ultra, the test results are automatically generated and the user is provided with printable test results. Thus, there is no
room for subjective interpretation of test results.
• No: if symptom questions were asked aNer the results of the reference test were known, or the CXR was interpreted with knowledge
of the results of the reference test.
• Unclear: if we cannot tell. For example, if it was unclear whether the CXR reader was blinded to the results of the reference standard.
Signalling question 2: If a threshold was used, was it prespecified?
For tuberculosis symptoms
This question was not applicable.
For CXR
Yes: if the study clearly reports positivity criteria for abnormalities suggestive of tuberculosis or other abnormalities.
No: if the study does not report the positivity criteria for abnormalities suggestive of tuberculosis or other abnormalities.
Unclear: if we cannot tell.
For Xpert MTB/RIF and Xpert Ultra
The threshold is prespecified in all versions of Xpert.
Yes: for all studies using Xpert MTB/RIF or Xpert Ultra as the index test.
Applicability: Are there concerns that the index test, its conduct, or its interpretation diJer from the review question?
• High concern: if the index tests were used for diagnosis rather than for screening.
• Low concern: if the index tests were performed with the intention to screen.
• Unclear concern: if we cannot tell.
Domain 3: Reference standard
Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?
Signalling question 1: Is the reference standard likely to correctly classify the target condition?
• Yes: for all studies using either a microbiological reference standard (i.e. culture, Xpert MTB/RIF, or Xpert Ultra) or a composite reference
standard as described in Reference standards. These are the acceptable reference tests for inclusion of studies in the review.
• Given the criteria for including studies in this review, all included studies will have a 'yes' response
Signalling question 2: Were the reference standard results interpreted without knowledge of the results of the index test?
• Yes: if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was clear that the
reference standard was performed at a separate laboratory and/or performed by diJerent people.
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• No: if the study stated that the reference standard result was interpreted with knowledge of the index test result.
• Unclear: if we cannot tell. We will also answer unclear if the study used a composite reference standard in which the index test was one
of the components of the reference standard. In the latter situation, the study may suJer from incorporation bias where there cannot be
blinding of the reference standard to the index test. Incorporation of the index test in the reference standard may increase the amount
of agreement between the index test results and reference standard thereby overestimating diagnostic accuracy.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question?
• High concern: if > 50% of tuberculosis cases identified in the study did not have microbiologically confirmed tuberculosis.
• Low concern: if the children with tuberculosis in the study have signs and symptoms or CXR abnormalities in addition to a positive
culture or Xpert result.
• Unclear concern: if we cannot tell.
Domain 4: Flow and timing
Risk of bias: Could the patient flow have introduced bias?
1. Was there an appropriate interval between the index test and reference standard?
• Yes: if the screening test and reference standard were applied (or specimens obtained) at the same time or within one week;
• No: if the time between the screening test and reference standard (specimen collection) was more than 1 week; and
• Unclear: if insuJicient information is provided to decide.
2. Did all patients receive the same reference standard?
• Yes: if all participants were evaluated with the reference standard, and if all or most participants were evaluated with the same test(s);
• No: if not all participants were evaluated with the reference standard, or participants received diJerent number of reference tests
• Unclear: if insuJicient information is provided to decide.
3. Were all patients included in the analysis?
• Yes: if all participants were included;
• No: if participants who participated were excluded, for example, cultures were lost or because they did not provide sputum for a
reference test;
• Unclear: if insuJicient information is provided to decide.
Judgements for ‘risk of bias' assessments for a given domain
• If we answered all signalling questions for a domain ‘yes', then we will judge risk of bias as ‘low'.
• If we answered all or most signalling questions for a domain ‘no', then we will judge risk of bias as ‘high'.
• If we answered only one signalling question for a domain ‘no', we will discuss further the risk of bias judgement.
• If we answered all or most signalling questions for a domain ‘unclear', then we will judge risk of bias as ‘unclear'.
• If we answered only one signalling question for a domain ‘unclear', we will discuss further the risk of bias judgement for the domain.
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